查看文章

The development of new disease biomarkers is essential for the progress of personalized medicine. This clinical approach, allows a great number of patients to access more efficient and safer therapeutic protocols, based on molecular findings in tissue samples obtained from patients for diagnostic or therapeutic purposes.

Biobanks, as repositories of human biological samples, have the responsibility to provide researchers with samples of known quality and an estimated potential for the analysis of DNA, RNA, proteins and antigenicity. A key element in this context is the knowledge, control and registration of all pre-analytical factors related to the final analytical performance of samples. This issue is particularly complex when dealing with samples from a wide range of tissues, obtained through various procedures (biopsy, resection or postmortem) and potentially tested with different analytical procedures.